FIELD: biotechnology.
SUBSTANCE: monoclonal antibody that binds to IL17A is proposed. The present invention also discloses a nucleic acid encoding said antibody, an expression vector and a host cell containing the sequence of said nucleic acid, and a method for producing the antibody. In addition, the invention is related to an antibody-drug conjugate, pharmaceutical composition and kit, which are used for treatment of psoriasis.
EFFECT: said monoclonal antibody specifically binds IL17A protein with high affinity, has superior or equivalent ability to block IL17A and IL17A/F-induced inflammatory cytokine secretion by human HFF epidermal fibroblasts compared to comparable drugs, and has improved in vivo efficacy.
22 cl, 9 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| FUSION PROTEIN COMPRISING IL-12 AND ANTI-FAP ANTIBODY, AND USE THEREOF | 2021 |
|
RU2831612C1 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| EphA4 ANTIBODY | 2020 |
|
RU2816371C2 |
| ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
